ADMA BIOLOGICS, INC.
Company Stats
- Market Cap
- $2.2B
- as of Sep 30, 2026
- Shares Outstanding
- 224.0M
- Free Float
- 91.0%
Income Statement
- Revenue
- $510.2M
- Operating Income
- $191.4M
- Net Income
- $146.9M
- EBITDA
- $199.4M
- Revenue Growth, 3Y
- 49.0%
- FCF Margin, 3Y Avg
- 11.0%
- FCF Margin, Worst Year
- 1.6%
Cash Flow
- Free Cash Flow
- $27.8M
- FCF Yield
- 1.2%
- Owner FCF Yield
- 0.3%
Balance Sheet
- Cash & Equivalents
- $87.6M
Returns & Capital
- Share Repurchases
- $31.9M
- Buyback Yield, 3Y Avg
- 0.5%
- SBC, 3Y Avg
- $13.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $510.2M | $27.8M | 5.5% |
| FY2024 | $426.5M | $110.4M | 25.9% |
| FY2023 | $258.2M | $4.0M | 1.6% |
| FY2022 | $154.1M | -$73.4M | -47.6% |
| FY2021 | $80.9M | -$125.9M | -155.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back